ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia (CML), dasatinib inhibits the deregulated tyrosine kinase activity of BCR-ABL, which is crucial for the growth and proliferation of leukemia cells [100,101].